367 results on '"Cambridge G"'
Search Results
2. OP0007 INCIDENCE, PREVALENCE AND CO-OCCURRENCE OF AUTOIMMUNE DISORDERS, TRENDS OVER TIME AND BY AGE, SEX AND SOCIOECONOMIC STATUS. A POPULATION-BASED STUDY IN 22 MILLION INDIVIDUALS.
3. AB0017 HOW DO B CELLS EVADE RITUXIMAB THERAPY IN AUTOIMMUNITY; IS IT TIME TO TARGET THE CD19+CD20- B CELLS?
4. The effect of B-cell depletion therapy on serological evidence of B-cell and plasmablast activation in patients with rheumatoid arthritis over multiple cycles of rituximab treatment
5. B cell phenotypes in patients with rheumatoid arthritis relapsing after rituximab: expression of B cell‐activating factor‐binding receptors on B cell subsets
6. Extended B cell phenotype in patients with myalgic encephalomyelitis/chronic fatigue syndrome: a cross-sectional study
7. Effect of rituximab on B cell phenotype and serum B cell-activating factor levels in patients with thrombotic thrombocytopenic purpura
8. B cell depletion therapy in rheumatic disease
9. A RETROSPECTIVE SEVEN-YEAR ANALYSIS OF THE USE OF B-CELL DEPLETION THERAPY IN SYSTEMATIC LUPUS ERYTHEMATOSUS AT UNIVERSITY COLLEGE LONDON HOSPITAL: THE FIRST FIFTY PATIENTS: C01
10. B cell depletion therapy in systemic lupus erythaematosus: relationships among serum B lymphocyte stimulator levels, autoantibody profile and clinical response
11. B cell depletion therapy for patients with systemic lupus erythaematosus results in a significant drop in anticardiolipin antibody titres
12. Repeated B-cell depletion in clinical practice
13. Repeated B lymphocyte depletion with rituximab in rheumatoid arthritis over 7 yrs
14. Bone marrow B-lineage cells in patients with rheumatoid arthritis following rituximab therapy
15. B Cell Depletion Therapy in Systemic Lupus Erythematosus: Effect on Autoantibody and Antimicrobial Antibody Profiles
16. Repeated B cell depletion in treatment of refractory systemic lupus erythematosus
17. B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients
18. Anti-endothelial cell antibodies in inflammatory bowel disease
19. Therapeutics 2: OP67. FOLLOW UP STUDY OF B-LYMPHOCYTE DEPLETION IN THE TREATMENT OF PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS
20. Prospects for B-cell-targeted therapy in autoimmune disease
21. B lymphocyte depletion therapy with rituximab in rheumatoid arthritis
22. An IgM class anti-neutrophil cytoplasm antibody inhibits neutrophil adhesion and apoptosis via a Syk dependent signaling cascade
23. An open study of B lymphocyte depletion in systemic lupus erythematosus
24. Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion
25. Do self-perpetuating B lymphocytes drive human autoimmune disease?
26. A comparison of the characteristics of circulating anti-myeloperoxidase autoantibodies in vasculitis with those in non-vasculitic conditions
27. A COMPARISON OF THE VARIABLE REGION GENES OF TWO HUMAN MONOCLONAL ANTIBODIES TO MYELOPEROXIDASE.
28. FCγRIIa POLYMORPHISM IN ANCA-RELATED VASCULITIS
29. Correlation of 9G4 idiotope with disease activity in patients with systemic lupus erythematosus
30. Differential distribution of FcγRIIIa in normal human tissues and co-localization with DAF and fibrillin-1: implications for immunological microenvironments
31. Restricted expression of FcγRIII (CD16) in synovium and dermis: implications for tissue targeting in rheumatoid arthritis (RA)
32. Expression of molecules involved in B lymphocyte survival and differentiation by synovial fibroblasts
33. Analysis of immunoglobulin variable region genes of a human IgM anti-myeloperoxidase antibody derived from a patient with vasculitis
34. Anti-myeloperoxidase antibodies in patients with rheumatoid arthritis: prevalence, clinical correlates and IgG subclass
35. CD24 Expression and B Cell Maturation Shows a Novel Link With Energy Metabolism: Potential Implications for Patients With Myalgic Encephalomyelitis/Chronic Fatigue Syndrome
36. Licensed To Kill
37. Prick-Tests and Serological Tests in the Diagnosis of Allergic Reactivity to Enzymes Used in Washing Products
38. AB0443 Infusion reactions to rituximab in systemic lupus erythematosus: a retrospective analysis
39. AB0124 Serological measures of b cell function in patients with sle; how robust are they over time?
40. FRI0042 BAFF-R expression in naÏve CD5+IGM+ B cells in rheumatoid arthritis patients repopulating after rituximab
41. INCIDENCE, PREVALENCE AND CO-OCCURRENCE OF AUTOIMMUNE DISORDERS, TRENDS OVER TIME AND BY AGE, SEX AND SOCIOECONOMIC STATUS. A POPULATION-BASED STUDY IN 22 MILLION INDIVIDUALS.
42. Internalization of rituximab and the efficiency of B cell depletion in rheumatoid arthritis and systemic lupus erythematosus
43. AB0372 Treatment To Target Following Initiation of Treatment with Rituximab in Rheumatoid Arthritis: Real Life Experience
44. OP0159 Improving B-Cell Depletion in Rheumatoid Arthritis and Systemic Lupus Erythematosus: Resistance To Rituximab and The Potential of Obinutuzumab
45. A10.03 B cell depletion with rituximab in patients with rheumatoid arthritis: Multiplex bead array reveals kinetics ofigg and iga autoantibodies to citrullinated antigens
46. Natural history of left ventricular function in neonatal coxsackie myocarditis
47. Some effects of lignocaine on cultured mouse peritoneal macrophages
48. IX Eular Workshop for Rheumatology Research: Molecular biology of autoantigens, autoantibodies and immunopeptides. Vienna, Austria, March 9–12, 1989
49. DIMETHYL FUMARATE MODULATES T CELL METABOLISM AND FUNCTION IN SYSTEMIC LUPUS ERYTHEMATOSUS PATIENT SAMPLES.
50. HOW DO B CELLS EVADE RITUXIMAB THERAPY IN AUTOIMMUNITY; IS IT TIME TO TARGET THE CD19+CD20-B CELLS?
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.